Amgen Inc. (AMGN): Price and Financial Metrics


Amgen Inc. (AMGN): $255.31

-3.47 (-1.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

AMGN Stock Summary

  • Amgen Inc's market capitalization of $149,462,628,593 is ahead of 98.54% of US-listed equities.
  • AMGN's went public 35.33 years ago, making it older than 92.8% of listed US stocks we're tracking.
  • The volatility of Amgen Inc's share price is greater than that of only 1.87% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Amgen Inc, a group of peers worth examining would be AZN, TXN, BA, SNY, and LLY.
  • Visit AMGN's SEC page to see the company's official filings. To visit the company's web site, go to www.amgen.com.

AMGN Stock Price Chart Interactive Chart >

Price chart for AMGN

AMGN Price/Volume Stats

Current price $255.31 52-week high $276.69
Prev. close $258.78 52-week low $210.28
Day low $253.66 Volume 2,508,141
Day high $258.48 Avg. volume 2,624,665
50-day MA $241.02 Dividend yield 2.72%
200-day MA $239.63 Market Cap 147.01B

Amgen Inc. (AMGN) Company Bio


Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.

AMGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$255.31$134.84 -47%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Amgen Inc. To summarize, we found that Amgen Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Amgen Inc ended up being:

  • The compound growth rate in the free cash flow of Amgen Inc over the past 5.52 years is 0.02%; that's higher than merely 24.54% of free cash flow generating stocks in the Healthcare sector.
  • Amgen Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 18.22% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-48%
1%-48%
2%-47%
3%-47%
4%-46%
5%-46%

EGRX, PHG, A, DXCM, and AZN can be thought of as valuation peers to AMGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


AMGN Latest News Stream


Event/Time News Detail
Loading, please wait...

AMGN Latest Social Stream


Loading social stream, please wait...

View Full AMGN Social Stream

Latest AMGN News From Around the Web

Below are the latest news stories about Amgen Inc that investors may wish to consider to help them evaluate AMGN as an investment opportunity.

Amgen Completes The Acquisition Of Five Prime Therapeutics

Amgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had previously announced a tender offer to buy all outstanding common stock at the price of $38.00 per share in cash. The aggregate payment that was to be made for the merger is $1.9B, excluding transaction expenses. Amgen is a biotech company that focuses on unlocking biological potential and innovations that cater to patients suffering from serious illnesses. Amgen (AMGN) focuses on unmet needs in the human therapeutics field, and Five Prime Therapeutics (FPRX) will add to its overall oncology portfolio.

Neha Gupta on TipRanks | April 20, 2021

Amgen’s Bemarituzumab Receives Breakthrough Therapy Designation

Amgen’s investigational treatment bemarituzumab has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration based on results from the Phase 2 FIGHT trial. The designation is for the treatment of gastric and gastroesophageal adenocarcinoma in combination with fluoropyrimidine, leucovorin, and oxaliplatin. Amgen (AMGN) Executive Vice president of Research and Development, David M. Reese, M.D., said, “The FIGHT trial is the first study to evaluate targeting the overexpression of FGFR2b in cancer. Bemarituzumab demonstrated clinically meaningful outcomes in key endpoints for patients with advanced gastric or gastroesophageal cancer as a frontline therapy.

Kailas Salunkhe on TipRanks | April 20, 2021

Amgen's Bemarituzumab Scores Breakthrough Therapy Tag For Gastric, GEJ Cancers

The FDA has granted Breakthrough Therapy Designation to Amgen Inc's (NASDAQ: AMGN ) bemarituzumab for patients with gastric and gastroesophageal (GEJ) adenocarcinoma. The designation covers bemarituzumab as first-line treatment of fibroblast growth factor receptor 2b, overexpressing and human epidermal growth factor receptor 2-negative, metastatic and locally advanced … Full story available on Benzinga.com

Benzinga | April 20, 2021

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | April 20, 2021

Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for its drug candidates Piclidenoson and Namodenoson in the U.S. and Europe. As part of marketing applications in the U.S. and Europe, both regulators require specific preclinical data to be submitted along with the pivotal Phase 3 data. Piclidenoson is now being evaluated in the COMFORT Phase 3 clinical study designed to establish Piclidenoson's superiority compared to placebo and non-inferiority compared to Amgen, Inc's (NASDAQ: AMGN) Otezla (Apremilast) for moderate-to-severe plaque psoriasis. A Phase 3 study of Namodenoson in the treatment of hepatocellular cancer (HCC) is expected to commence in the fourth quarter of this year. Pri...

Yahoo | April 20, 2021

Read More 'AMGN' Stories Here

AMGN Price Returns

1-mo 4.19%
3-mo 1.46%
6-mo 14.00%
1-year 14.46%
3-year 59.31%
5-year 80.01%
YTD 11.87%
2020 -1.99%
2019 27.60%
2018 15.23%
2017 22.27%
2016 -7.56%

AMGN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AMGN Dividend History

Continue Researching AMGN

Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:

Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.1581 seconds.